ClariVest Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

ClariVest Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-37,839	Closed	-$2.27M	–	667
2019 Q3	$2.27M	Sell	37,839 -15,100	-29%	-$1.12M	0.05%	241
2019 Q2	$4.47M	Buy	52,939 +21,096	+66%	+$1.9M	0.1%	173
2019 Q1	$3.04M	Sell	31,843 -2,434	-7%	-$218K	0.06%	251
2018 Q4	$2.43M	Buy	34,277 +13,235	+63%	+$1.01M	0.05%	270
2018 Q3	$1.8M	Sell	21,042 -619	-3%	-$62K	0.03%	335
2018 Q2	$2.51M	Buy	21,661 +10,761	+99%	+$1.07M	0.04%	310
2018 Q1	$882K	Sell	10,900 -4,300	-28%	-$331K	0.02%	442
2017 Q4	$892K	Buy	15,200 +1,700	+13%	+$85.1K	0.02%	434
2017 Q3	$631K	Buy	13,500 +100	+0.7%	+$4.02K	0.01%	369
2017 Q2	$482K	Hold	13,400	–	–	0.01%	388
2017 Q1	$413K	Buy	13,400 +100	+0.8%	+$3.11K	0.01%	408
2016 Q4	$446K	Buy	+13,300	New	+$381K	0.01%	409

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

ClariVest Asset Management's ENTA Position: Q4 2019 in Review

ClariVest Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2019, closing a stake of 37,839 shares — an estimated $2.27M sold.

ClariVest Asset Management first reported a position in ENTA in Q4 2016 and held it in 12 quarters. The position peaked at $4.47M in Q2 2019. 171 funds tracked by Wall St. Rank hold ENTA as of Q4 2019.

ClariVest Asset Management reported no remaining Enanta Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
ClariVest Asset Management sold 37,839 Enanta Pharmaceuticals shares in Q4 2019, an estimated $2.27M.
ClariVest Asset Management first reported a position in Enanta Pharmaceuticals in Q4 2016 and held it in 12 quarters.
ClariVest Asset Management's Enanta Pharmaceuticals position peaked at $4.47M in Q2 2019.
171 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2019.

Based on ClariVest Asset Management's 13F filing for Q4 2019, filed 12 Feb 2020.